Last reviewed · How we verify
Azithromycin Pill
Azithromycin Pill, marketed by Rambam Health Care Campus, is an established antibiotic with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and broad spectrum of activity against common bacterial infections. The primary risk is the potential increase in generic competition following the 2028 patent expiry.
At a glance
| Generic name | Azithromycin Pill |
|---|---|
| Sponsor | Rambam Health Care Campus |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Azithromycin Before Induction (PHASE1)
- Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age (PHASE4)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks (NA)
- Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease (PHASE2)
- Azithromycin-Prevention in Labor Use Study (A-PLUS) (PHASE3)
- Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections (NA)
- Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin Pill CI brief — competitive landscape report
- Azithromycin Pill updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI